Canada · Delayed Price · Currency is CAD BioVaxys Technology Statistics
Total Valuation
CSE:BIOV has a market cap or net worth of CAD 8.07 million. The enterprise value is 8.20 million.
| Market Cap | 8.07M |
| Enterprise Value | 8.20M |
Important Dates
The next estimated earnings date is Friday, March 13, 2026.
| Earnings Date | Mar 13, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
CSE:BIOV has 29.34 million shares outstanding. The number of shares has increased by 61.26% in one year.
| Current Share Class | 29.34M |
| Shares Outstanding | 29.34M |
| Shares Change (YoY) | +61.26% |
| Shares Change (QoQ) | +1.14% |
| Owned by Insiders (%) | 11.69% |
| Owned by Institutions (%) | n/a |
| Float | 25.91M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | n/a |
| PB Ratio | -2.22 |
| P/TBV Ratio | n/a |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | -1.37 |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 0.28
| Current Ratio | 0.28 |
| Quick Ratio | 0.10 |
| Debt / Equity | n/a |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | n/a |
Financial Efficiency
| Return on Equity (ROE) | n/a |
| Return on Assets (ROA) | -152.79% |
| Return on Invested Capital (ROIC) | n/a |
| Return on Capital Employed (ROCE) | 127.38% |
| Revenue Per Employee | n/a |
| Profits Per Employee | n/a |
| Employee Count | n/a |
| Asset Turnover | n/a |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -63.33% in the last 52 weeks. The beta is 0.13, so CSE:BIOV's price volatility has been lower than the market average.
| Beta (5Y) | 0.13 |
| 52-Week Price Change | -63.33% |
| 50-Day Moving Average | 0.27 |
| 200-Day Moving Average | 0.37 |
| Relative Strength Index (RSI) | 52.87 |
| Average Volume (20 Days) | 34,158 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
| Revenue | n/a |
| Gross Profit | n/a |
| Operating Income | -4.64M |
| Pretax Income | -5.97M |
| Net Income | -5.97M |
| EBITDA | n/a |
| EBIT | -4.64M |
| Earnings Per Share (EPS) | -0.22 |
Balance Sheet
The company has 4,080 in cash and 133,720 in debt, giving a net cash position of -129,640 or -0.00 per share.
| Cash & Cash Equivalents | 4,080 |
| Total Debt | 133,720 |
| Net Cash | -129,640 |
| Net Cash Per Share | -0.00 |
| Equity (Book Value) | -3.64M |
| Book Value Per Share | -0.12 |
| Working Capital | -3.64M |
Cash Flow
| Operating Cash Flow | -2.97M |
| Capital Expenditures | n/a |
| Free Cash Flow | n/a |
| FCF Per Share | n/a |
Margins
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
CSE:BIOV does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -61.26% |
| Shareholder Yield | -61.26% |
| Earnings Yield | -73.98% |
| FCF Yield | n/a |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
The last stock split was on September 11, 2025. It was a reverse split with a ratio of 0.1.
| Last Split Date | Sep 11, 2025 |
| Split Type | Reverse |
| Split Ratio | 0.1 |
Scores
| Altman Z-Score | n/a |
| Piotroski F-Score | 1 |